Peptides and Diabetes: GLP-1, GIP, and the Future of Metabolic Medicine

Written by Adam Maggio | Medically reviewed by Dr. James Whitfield, DO, FACOI

GLP-1 receptor agonists (semaglutide) and dual GLP-1/GIP agonists (tirzepatide) have revolutionized type 2 diabetes treatment. They reduce HbA1c by 1.5–2%, promote significant weight loss, and reduce cardiovascular events. They represent the most significant advance in diabetes pharmacotherapy in decades.

The Incretin Revolution in Diabetes

Type 2 diabetes management has been transformed by the development of incretin-based therapies — medications that work through the body's natural gut hormone systems to regulate blood glucose, body weight, and cardiovascular risk. GLP-1 receptor agonists and the newer dual GLP-1/GIP agonists represent the most significant advance in diabetes pharmacotherapy since the introduction of metformin, and their benefits extend far beyond glycemic control.

GLP-1 Physiology

Glucagon-like peptide-1 (GLP-1) is a hormone produced by L-cells in the intestinal mucosa in response to food intake. It stimulates glucose-dependent insulin secretion (reducing hyperglycemia without causing hypoglycemia), suppresses glucagon secretion (reducing hepatic glucose production), slows gastric emptying (reducing postprandial glucose spikes), and acts on the hypothalamus to reduce appetite and food intake. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) mimic and amplify these effects.

GIP Physiology and Tirzepatide

Glucose-dependent insulinotropic polypeptide (GIP) is the other major incretin hormone. While GLP-1 agonism alone produces significant metabolic benefits, adding GIP receptor agonism (as in tirzepatide) produces synergistic effects on weight loss and glycemic control. The SURPASS clinical trial program demonstrated that tirzepatide reduces HbA1c by up to 2.4% and body weight by up to 22% — outcomes that rival bariatric surgery.

Cardiovascular Benefits

Beyond glycemic control and weight loss, GLP-1 agonists have demonstrated direct cardiovascular protective effects. The LEADER trial (liraglutide), SUSTAIN-6 trial (semaglutide), and REWIND trial (dulaglutide) all demonstrated significant reductions in major adverse cardiovascular events (MACE) in patients with type 2 diabetes and cardiovascular disease. These cardiovascular benefits appear to be partly independent of the glycemic and weight loss effects.

The Future: Triple Agonists and Beyond

The next generation of metabolic peptides includes triple agonists targeting GLP-1, GIP, and glucagon receptors simultaneously. Retatrutide, a triple agonist, has demonstrated weight loss of approximately 24% in Phase 2 trials — potentially exceeding even tirzepatide's efficacy. The rapid pace of development in this field suggests that the coming decade will bring even more potent and comprehensive metabolic therapies.